Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World LEIDEN, The ...
AMSTERDAM, Aug 17 (Reuters) - Dutch biotech group Crucell swung to a second-quarter net profit as it benefited from production problems at one of its key rivals, and it raised its full-year guidance ...
Leiden, the Netherlands (July 8, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Crucell and sanofi pasteur reached an ...
Leiden, The Netherlands, 7 January 2009 - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today confirms that it is in friendly discussions with Wyeth that ...
U.S. healthcare giant Johnson & Johnson (NYSE:JNJ) has launched a $2.3 billion bid to takeover vaccine maker Crucell in an effort to catapult itself into the global vaccine market. Through its newly ...
Crucell’s prime malaria vaccine candidate will be teamed with boost vaccination component. The U.S. Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP) is ...
AMSTERDAM, April 11 (Reuters) - Dutch biotech firm Crucell will be delisted from Euronext Amsterdam after the close of trading on Monday, following its takeover by U.S. healthcare company Johnson & ...
Van Herk Groep has taken note of the announcement of 6 October 2010 that Johnson & Johnson (J&J) and the board of Crucell have reached agreement on J&J making a bid. Van Herk Groep has been a Crucell ...
LEIDEN, The Netherlands, July 29, 2009 – The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), ...
TRENTON, N.J. -- Johnson & Johnson said Wednesday it is buying Holland's Crucell NV for about $2.41 billion, marking the American health care giant's latest effort to gain a big foothold in the ...
Dutch biotechnology company Crucell has suffered a blow to its near-term product pipeline after calling time on Aerugen, a vaccine candidate for treating bacterial infections in patients with cystic ...
Leiden, The Netherlands, March 24, 2004 – Crucell N.V. (Euronext, NASDAQ: CRXL) and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, announced today a new collaboration on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results